Incyte Corporation (INCY) Announces Full Results From Proof-Of-Concept Phase II RECAP Trial Of Jakafi® (Ruxolitinib) In Combination With Capecitabine In Patients With Metastatic Pancreatic Cancer
6/3/2014 8:36:21 AM
CHICAGO--(BUSINESS WIRE)--Incyte Corporation (Nasdaq: INCY) today announced full results from RECAP, a Phase II trial of ruxolitinib, a JAK1/JAK2 inhibitor, in combination with capecitabine in second-line metastatic pancreatic cancer. The findings from this proof-of-concept trial showed that ruxolitinib plus capecitabine prolonged survival over capecitabine alone in patients with elevated C-reactive protein (CRP), a well-established marker of systemic inflammation (hazard ratio = 0.47; 95% CI, 0.26-0.85; P=0.01 (2-sided)). Patients in this subgroup treated with ruxolitinib plus capecitabine also achieved improvements in other efficacy measures including objective response rate, clinical benefit response, and weight gain. These data were presented at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.
Help employers find you! Check out all the jobs and post your resume.
comments powered by